

FORM PTO 1390 (REV 5-93)		US DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY DOCKET NUMBER 2006_0286A
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. §371			U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 10/570,133
International Application No. PCT/JP2004/012638	International Filing Date September 1, 2004	Priority Date Claimed September 1, 2003	
Title of Invention BETA-HYDROXY SHORT TO MEDIUM CHAIN FATTY ACID POLYMER			
Applicant(s) For DO/EO/US Kazunari USHIDA and Masaki KURIYAMA			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<ol style="list-style-type: none"> 1. <input type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. §371. 2. <input checked="" type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. §371. 3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. §371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. §371(b) and PCT Articles 22 and 39(1). 4. <input type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input type="checkbox"/> A copy of the International Application as filed (35 U.S.C. §371(c)(2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US) 6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. §371(c)(2)). 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. §371(c)(3)). <ol style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19. 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. §371(c)(4)). 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. §371(c)(5)). 			
Items 11. to 14. below concern other document(s) or information included:			
11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. ATTACHMENT J			
12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.			
13. <input type="checkbox"/> A FIRST preliminary amendment.			
<input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.			
14. <input type="checkbox"/> Other items or information:			

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Kazunari USHIDA et al. : **Mail Stop: PCT**
Serial No. 10/570,133 : Attorney Docket No. 2006_0286A
Filed March 1, 2006 :

BETA-HYDROXY SHORT TO MEDIUM
CHAIN FATTY ACID POLYMER
[Corresponding to PCT/JP2004/012638
Filed September 1, 2004]

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- ☒ each U.S. Patent and U.S. Patent application publication;
- ☐ each reference previously cited in the international application
PCT/_____; and/or
- ☐ each reference previously cited in prior parent application Serial No.
_____.

1a. ☒ This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the
above-entitled application, **or**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.R./

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

(1) ☐ the certification of paragraph 2 below is provided, **or**

(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

2. It is hereby certified

- a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
- b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.


3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.
4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
- a. ☐ a full or partial English language translation submitted herewith,
 - b. ☐ a foreign patent office search report (in the English language) submitted herewith,
 - c. ☒ the concise explanation contained in the specification of the present application at pages 1 to 27,

Reference DB (Brune et al.) is discussed on page 11 of the specification.
 - d. ☐ the concise explanation set forth in the attached English language abstract,
 - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☐ A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Kazunari USHIDA et al.

By


Matthew M. Jacob
Registration No. 25,154
Attorney for Applicants

MJ/kes
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
June 12, 2006

Sheet 1 of 5		INFORMATION DISCLOSURE STATEMENT							
FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Date Submitted to PTO: June 12, 2006				ATTY DOCKET NO. 2006_0286A		SERIAL NO. 10/570,133			
				APPLICANT Kazunari USHIDA et al.					
				FILING DATE March 1, 2006			GROUP		
FOREIGN PATENT DOCUMENTS									
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO		
	AA	92/09211	06/1992	WO					
	AB	99/34687	07/1999	WO					
	AC	83/00435	02/1983	WO					
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)									
	AD	Cook, S. et al., <i>Aliment. Pharmacol. Ther.</i> , Vol. 12, pp. 499 to 507 (1998).							
	AE	Hara, H., <i>Bioscience Microflora</i> , Vol. 21, No. 1, pp. 35 to 42 (2002).							
	AF	Andoh, A. et al., <i>Current Pharmaceutical Design</i> , Vol. 9, pp. 347 to 358 (2003).							
	AG	Harig, J. et al., <i>The New England Journal of Medicine</i> , Vol. 320, No. 1, pp. 23 to 28 (1989).							
	AH	Head, K. et al., <i>Alternative Medicine Review</i> , Vol. 8, No. 3, pp. 247 to 283 (2003).							
	AI	Goh, J. et al., <i>Aliment. Pharmacol. Ther.</i> , Vol. 17, pp. 307 to 320 (2003).							
	AJ	Hong, J. et al., <i>Aliment. Pharmacol. Ther.</i> , Vol. 15, pp. 1253 to 1262 (2001).							
	AK	Jacobasch, G. et al., <i>Int. J. Colorectal Dis.</i> , Vol. 14, pp. 201 to 211 (1999).							
	AL	Andoh, A. et al., <i>JPEN, Journal of Parenteral and Enteral Nutrition</i> , Vol. 23, No. 5, pp. S70 to S73 (1999).							
	AM	Kanauchi, O. et al., <i>Journal of Gastroenterology and Hepatology</i> , Vol. 14, pp. 880 to 888 (1999).							
EXAMINER					DATE CONSIDERED				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include cop. this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.R./

INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: June 12, 2006

ATTY DOCKET NO.
2006_0286ASERIAL NO.
10/570,133APPLICANT
Kazunari USHIDA et al.FILING DATE
March 1, 2006

GROUP

OTHER DOCUMENT(S) (including Author, Title, Date, Pertinent Pages, Etc.)

BA	Wächtershäuser, A. et al., <i>Eur. J. Nutr.</i> , Vol. 39, pp. 164 to 171 (2000).
BB	Welters, C. et al., <i>Dis. Colon Rectum</i> , Vol. 45, No. 5, pp. 621 to 627 (2002).
BC	Mortensen, F., et al., <i>J. Gastroenterology</i> , Vol. 31, pp. 302 to 303 (1996).
BD	Vernia, P. et al., <i>The Lancet</i> , Vol. 356, pp. 1232 to 1235 (2000).
BE	Rabbani, G. et al., <i>The Journal of Infectious Diseases</i> , Vol. 179, pp. 390 to 397 (1999).
BF	Rahman et al., <i>Gastroenterology</i> , Vol. 112, No. 4, A2 (1997).
BG	Ramakrishna, B.S. et al., <i>Gut</i> , Vol. 34, pp. 1215 to 1218 (1993).
BH	Rabbani, G. et al., <i>Gastroenterology</i> , Vol. 121, pp. 554 to 560 (2001).
BI	Ramakrishna, B.S., <i>The New England Journal of Medicine</i> , Vol. 342, No. 5, pp. 308 to 313 (2000).
BJ	Kanauchi, O. et al., <i>Biosci. Biotechnol. Biochem.</i> , Vol. 62, No. 9, pp. 1788 to 1790 (1998).
BK	Chen, H. et al., <i>Nutrition Research</i> , Vol. 20, No. 12, pp. 1725 to 1733 (2000).
BL	Chen, H. et al., <i>Journal of the American College of Nutrition</i> , Vol. 20, No. 1, pp. 44 to 49 (2001).
BM	Parisi, G. C., <i>Digestive Diseases and Sciences</i> , Vol. 47, No. 8, pp. 1697 to 1704 (2002).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include cop. this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.R./

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: June 12, 2006

ATTY DOCKET NO.
2006_0286ASERIAL NO.
10/570,133APPLICANT
Kazunari USHIDA et al.FILING DATE
March 1, 2006

GROUP

CA Bijkerk, C., *Aliment Pharmacol. Ther.*, Vol. 19, pp. 245 to 251 (2004).CB Fiordaliso, M. et al., *Lipids*, Vol. 30, No. 2, pp. 163 to 167 (1995).CC Delzenne, N. et al., *Am. J. Clin. Nutr.*, Vol. 73, pp. 456S to 458S (2001).CD Marcil, V. et al. *J. Nutr.*, Vol. 133, pp. 2180 to 2183 (2003).CE McIntyre, A. et al. *Gut*, Vol. 34, pp. 386 to 391 (1993).CF Perrin, P. et al., *Gut*, Vol. 48, pp. 53 to 61 (2001).CG D'Argenio, G. et al., *Gastroenterology*, Vol. 110, pp. 1727 to 1734 (1996).CH Leschelle, X. et al., *Eur. J. Biochem.*, Vol. 267, pp. 6435 to 6442 (2000).CI Augenlicht, L. et al., *Cancer Research*, Vol. 59, pp. 6005 to 6009 (1999).CJ Heerdt, B. et al., *Cancer Research*, Vol. 54, pp. 3288 to 3294 (1994).CK Heerdt, B. et al., *The Journal of Biological Chemistry*, Vol. 266, No. 28, pp. 19120 to 19126 (1991).CL Pouillart, P., *Life Sciences*, Vol. 63, No. 20, pp. 1739 to 1760 (1998).CM Anderson, A., *Microbiological Reviews*, Vol. 54, No. 4, pp. 450 to 472.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include cop. this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.R./

INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: June 12, 2006

ATTY DOCKET NO.
2006_0286ASERIAL NO.
10/570,133APPLICANT
Kazunari USHIDA et al.FILING DATE
March 1, 2006

GROUP

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

DA	Lee, S., <i>Biotechnology and Bioengineering</i> , Vol. 49, pp. 1 to 14 (1996).
DB	Brune, V. et al., <i>Z. Tierphysiol., Tierernährg. u. Futtermittelkde.</i> , Vol. 38, pp. 81 to 93 (1977).
DC	Forni, D. et al., <i>Ann. Zootech.</i> , Vol. 48, pp. 163 to 171 (1999).
DD	Forni, D. et al., <i>J. Anim. Physiol. A. Anim. Nutr.</i> , Vol. 81, pp. 31 to 40 (1999).
DE	Forni, D. et al., <i>J. Anim. Physiol. A. Anim. Nutr.</i> 81, pp. 41 to 50 (1999).
DF	Embleton, J. et al., <i>J. Microencapsulation</i> , Vol. 9, No. 1, pp. 73 to 87 (1992).
DG	Kusaka, S. et al., <i>Appl. Microbiol. Biotechnol.</i> , Vol. 47, pp. 140 to 143 (1997).
DH	McBee, R., <i>The Journal of Experimental Zoology Supplement</i> , Vol. 3, pp. 55 to 60 (1989).
DI	Stevens, C. et al., <i>Physiological Reviews</i> , Vol. 78, No. 2, pp. 393 to 427 (1998).
DJ	Marounek, M. et al., <i>Physiol. Res.</i> , Vol. 47, pp. 259 to 263 (1998).
DK	Jamroz, D. et al., <i>Comparative Biochemistry and Physiology Part A</i> , Vol. 131, pp. 657 to 668 (2002).
DL	Kihara, M. et al. <i>Comparative Biochemistry and Physiology Part A</i> , Vol. 132, pp. 333 to 340 (2002).
DM	Mountfort, D. et al., <i>Applied and Environmental Microbiology</i> , Vol. 68, No. 3, pp. 1374 to 1380 (2002).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include cop. this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.R./

INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: June 12, 2006

ATTY DOCKET NO.
2006_0286ASERIAL NO.
10/570,133APPLICANT
Kazunari USHIDA et al.FILING DATE
March 1, 2006

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	EA	4,663,308	05/1987	Saffran et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	EB	H11-092552	04/1999	JP			abstract only
	EC	H06-179618	06/1994	JP			abstract only
	ED	H10-324642	12/1998	JP			abstract only
	EE	2000-143538	05/2000	JP			abstract only

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	EF	Slater, S.C. et al., <i>Journal of Bacteriology</i> , Vol. 170, No. 10, pp. 4431 to 4436 (1988).
	EG	Schubert, P. et al., <i>Journal of Bacteriology</i> , Vol. 170, No. 12, pp. 5837 to 5847 (1988).
	EH	Poirier, Y. et al., <i>Science</i> , Vol. 256, pp. 520 to 523 (1992).
	EI	Younes, H. et al., <i>The Journal of Nutrition</i> , Vol. 125, No. 4, pp. 1010 to 1016 (1995).
	EJ	Okayasu, I. et al., <i>Gastroenterology</i> , Vol. 98, pp. 694 to 702 (1990).
	EK	Tanaka, Y. et al., <i>Eur. J. Biochem.</i> , Vol. 118, pp. 177 to 182 (1981).
	EL	Mochizuki, M. et al., <i>Polymers for Advanced Technologies</i> , Vol. 8, pp. 203 to 209 (1996).

EXAMINER

/James Rogers/

DATE CONSIDERED

08/11/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include cop. this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.R./